Breaking News

Cobra Biologics Gains Approval for R&D Tax Credit

April 1, 2014

Offers R&D incentive for French companies

Cobra Biologics has been recognized by the French Ministry of Higher Education and Research (MESR) as an approved service provider for its antibody and recombinant protein services for the period 2013 to 2015. The approval allows French companies that outsource their R&D programs to Cobra’s centre of excellence, to receive a research tax credit.
 
The tax credit, which covers 30% of all R&D expenses up to €100 million, and 5% above this threshold, aims to encourage R&D efforts and enhance investments in France. 

Peter Coleman, chief executive officer of Cobra Biologics, said, “CIR is a real benefit to our French customers as it encourages them to invest in innovative drugs that are ultimately the driving force for the medicines of tomorrow.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent